Neurology

 

Neurology

Simoa® is not just a better way to detect CNS biomarkers
It's a 1,000-times better way

The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, has the potential to transform the way brain injuries and diseases are diagnosed.

Simoa assays can detect neurological biomarkers, such as Neurofilament Light (NfL),Tau, GFAP and several otohers associated with brain injury and disease. With Simoa, these informative markers can be detected at much earlier stages, in blood, serum or plasma, enabling better understanding of the long-term effects and disease pathology without invasive measures. Quanterix has a strategic focus in neurodegeneration, neuroinflammation, traumatic brain injuries (TBI) and multiple sclerosis (MS)  and is working with a rapidly growing network of academic researchers and pharmaceutical and biotech partners to drive advancements in head health research.

 

Latest Publications

Quanterix' digital health solution, Simoa, is changing the way academics, researchers, scientists and drug manufacturers measure and detect Alzheimer's, Parkinsons' Disease, Traumatic Brain Injury (TBI) and concussions. Quanterix' focus in neurology and neurodegeneration is growing with a network of academic researchers and pharmaceutical and biotech partners. Learn about Simoa's advancements in detecting neurological biomarkers by exploring our scientific publications and journals.

Latest News

09.25
September 25-28, 2019 | Stuttgart, Germany | Booth C44   More Information
07.15
Kapogiannis D, Mustapic M, Shardell MD, Berkowitz ST, Diehl TC, Spangler RD, Tran J, Lazaropoulos MP, Chawla S, Gulyani S, Eitan E, An Y, Huang CW, Oh ES, Lyketsos CG, Resnick SM, Goetzl EJ and Ferrucci L